바이오스펙테이터

바이오스펙테이터 Seunghyun Chon 기자

Kolon life science said, on the 7th, that it has exceeded 100 cases of osteoarthritis gene therapy using their drug "Invossa-K".

Approved in Korea in July, Invossa-K is a gene therapy developed for the first time in Korea, which has chondrocytes derived from chondrocytes as a main component, using an anti-inflammatory 'TGF-β1 gene'.

Invossa-K has started their first therapy case in early November and now has exceeded 100 cases in only one month. Currently more than forty hospitals use this injection therapy, and it is presumed to be more than a hundred hospitals will use Invossa therapy by this year.

Also, it is steadily increased in a number of gene therapy medical centers (hospitals) where can execute gene therapy, using Invossa. The number of medical centers was eighty at first, but now the number is reaching to two hundred-twenty-five, making consultation and therapy of Invossa much more convenient. P&T committee of fifteen general hospitals had passed Invossa as their formulary.

Lee-Woo Suk, CEO of Kolon life science said, "Year of 2017 was the starting point to become a new game changer in the domestic osteoarthritis treatment market through the launch of Invossa. I hope we can definitely pioneer a new path to osteoarthritis treatment domestically and globally including Southeast Asia in 2018."